Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Pacira Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Pacira Pharmaceuticals shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira Pharmaceuticals employs 697 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $58.63 |
|---|---|
| 52-week range | $45.05 - $82.16 |
| 50-day moving average | $64.18 |
| 200-day moving average | $61.97 |
| Wall St. target price | $77.73 |
| PE ratio | 68.4505 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $58.63 from 2022-06-29
| 1 week (2022-06-22) | 8.11% |
|---|---|
| 1 month (2022-05-27) | -9.02% |
| 3 months (2022-03-30) | -22.52% |
| 6 months (2021-12-30) | -3.71% |
| 1 year (2021-06-30) | -3.38% |
|---|---|
| 2 years (2020-06-30) | 11.74% |
| 3 years (2019-06-28) | 34.81% |
| 5 years (2017-06-29) | 21.64% |
Valuing Pacira Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pacira Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Pacira Pharmaceuticals shares trade at around 68x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pacira Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $177 million.
The EBITDA is a measure of a Pacira Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $580.5 million |
|---|---|
| Operating margin TTM | 22.96% |
| Gross profit TTM | $345.7 million |
| Return on assets TTM | 5.24% |
| Return on equity TTM | 5.65% |
| Profit margin | 6.62% |
| Book value | $15.75 |
| Market capitalisation | $2.6 billion |
TTM: trailing 12 months
We're not expecting Pacira Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Pacira Pharmaceuticals's shares have ranged in value from as little as $45.05 up to $82.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira Pharmaceuticals's is 0.8857. This would suggest that Pacira Pharmaceuticals's shares are less volatile than average (for this exchange).
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.